David Shaw’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.53M | Buy |
+5,100
| New | +$2.26M | ﹤0.01% | 2997 |
|
|
2026
Q1 | – | Sell |
-9,400
| Closed | -$4.26M | – | 5106 |
|
|
2025
Q4 | $4.26M | Sell |
9,400
-3,000
| -24% | -$1.29M | ﹤0.01% | 2446 |
|
|
2025
Q3 | $4.86M | Buy |
12,400
+7,400
| +148% | +$3.09M | ﹤0.01% | 2231 |
|
|
2025
Q2 | $2.23M | Buy |
5,000
+2,800
| +127% | +$1.29M | ﹤0.01% | 2665 |
|
|
2025
Q1 | $1.07M | Buy |
+2,200
| New | +$1.03M | ﹤0.01% | 3047 |
|
|
2023
Q4 | – | Sell |
-1,400
| Closed | -$487K | – | 4639 |
|
|
2023
Q3 | $487K | Buy |
+1,400
| New | +$490K | ﹤0.01% | 3439 |
|
|
2023
Q1 | – | Sell |
-8,000
| Closed | -$2.31M | – | 4905 |
|
|
2022
Q4 | $2.31M | Hold |
8,000
| – | – | ﹤0.01% | 2822 |
|
|
2022
Q3 | $2.32M | Sell |
8,000
-10,000
| -56% | -$2.88M | ﹤0.01% | 2861 |
|
|
2022
Q2 | $5.07M | Sell |
18,000
-2,400
| -12% | -$642K | 0.01% | 2109 |
|
|
2022
Q1 | $5.32M | Sell |
20,400
-30,500
| -60% | -$7.24M | 0.01% | 2238 |
|
|
2021
Q4 | $11.2M | Sell |
50,900
-48,300
| -49% | -$9.39M | 0.01% | 1566 |
|
|
2021
Q3 | $18M | Buy |
99,200
+40,200
| +68% | +$7.85M | 0.02% | 1088 |
|
|
2021
Q2 | $11.9M | Buy |
59,000
+35,000
| +146% | +$7.32M | 0.01% | 1355 |
|
|
2021
Q1 | $5.16M | Buy |
+24,000
| New | +$5.27M | 0.01% | 1821 |
|
|
2018
Q2 | – | Sell |
-25,000
| Closed | -$4.08M | – | 3910 |
|
|
2018
Q1 | $4.08M | Buy |
25,000
+5,000
| +25% | +$817K | 0.01% | 1545 |
|
|
2017
Q4 | $3M | Hold |
20,000
| – | – | ﹤0.01% | 1850 |
|
|
2017
Q3 | $3.04M | Sell |
20,000
-20,000
| -50% | -$3.01M | ﹤0.01% | 1745 |
|
|
2017
Q2 | $5.16M | Hold |
40,000
| – | – | 0.01% | 1310 |
|
|
2017
Q1 | $4.37M | Hold |
40,000
| – | – | 0.01% | 1373 |
|
|
2016
Q4 | $2.95M | Buy |
40,000
+27,700
| +225% | +$2.25M | 0.01% | 1716 |
|
|
2016
Q3 | $1.07M | Buy |
12,300
+2,300
| +23% | +$217K | ﹤0.01% | 2344 |
|
|
2016
Q2 | $860K | Hold |
10,000
| – | – | ﹤0.01% | 2505 |
|
|
2016
Q1 | $795K | Buy |
+10,000
| New | +$905K | ﹤0.01% | 2513 |
|
|
2015
Q3 | – | Sell |
-1,700
| Closed | -$210K | – | 3915 |
|
|
2015
Q2 | $210K | Buy |
+1,700
| New | +$214K | ﹤0.01% | 3565 |
|
|
2014
Q3 | – | Sell |
-5,000
| Closed | -$473K | – | 4408 |
|
|
2014
Q2 | $473K | Buy |
+5,000
| New | +$351K | ﹤0.01% | 3574 |
|
Other funds holding VRTX
David Shaw's VRTX Position: Q2 2026 in Review
David Shaw reduced its Vertex Pharmaceuticals (VRTX) stake by 99% in Q2 2026, selling an estimated $109M and leaving 3,105 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #3417.
David Shaw first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $311M in Q3 2021. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- David Shaw held 3,105 shares of Vertex Pharmaceuticals worth $1.54M as of Q2 2026.
- David Shaw sold 245,855 Vertex Pharmaceuticals shares in Q2 2026, an estimated $109M.
- Vertex Pharmaceuticals made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3417 holding.
- David Shaw first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- David Shaw's Vertex Pharmaceuticals position peaked at $311M in Q3 2021.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.